RPG Life Sciences Ltd (RPGLIFE)
₹2,673.40
Mkt cap
₹4,501 Cr
P/E ratio
38.60
P/B
7.30
Div yield
0.88%
ROE
19.30%
ROCE
25.70%
EPS (TTM)
₹69.26
Book value
₹366
52W range
1,744–3,017
Sector
Healthcare
Price history
Previous close
Incorporated in 2007, RPG Life Sciences Ltd manufactures and markets Formulations (Finished Dosage Forms) and Active Pharma Ingredients [1]
NSE RPGLIFEBSE 532983
Health check
Constructive
ValuationFair
ProfitabilityStrong
GrowthModerate
TechnicalsNeutral
52-week range
−11.39% from high₹2,673
₹1,744+53.29% from low₹3,017
Current
₹2,673.40
Prev close
₹2,721.60
Day
−1.77%
Price performance
1D
−2.08%
1W
+1.37%
1M
+0.14%
3M
+25.88%
6M
+47.74%
1Y
+13.90%
YTD
+15.61%
Financials
Revenue, profit & margin
P/E ratio
38.6×
RPGLIFE is 14% above the sector median of 34.0×
RPGLIFE38.6×
Sector median34.0×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 148 | 154 | 154 | 127 | 165 | 172 | 173 | 143 | 169 | 182 | 180 | 177 | 196 | |
| Expenses | 116 | 116 | 116 | 106 | 126 | 126 | 124 | 118 | 133 | 143 | 140 | 144 | 152 | |
| Operating Profit | 32 | 37 | 38 | 21 | 39 | 46 | 49 | 25 | 35 | 39 | 40 | 33 | 44 | |
| OPM % | 22% | 24% | 25% | 16% | 24% | 27% | 28% | 18% | 21% | 21% | 22% | 19% | 22% | |
| Other Income | 2 | 2 | 2 | 2 | 2 | -25 | 3 | 115 | 5 | 16 | -5 | 13 | 4 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | |
| Depreciation | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 6 | 6 | |
| Profit before tax | 30 | 35 | 36 | 18 | 36 | 15 | 47 | 135 | 35 | 49 | 29 | 40 | 41 | |
| Tax % | 26% | 26% | 26% | 25% | 26% | 72% | 26% | 13% | 26% | 25% | 24% | 26% | 26% | |
| Net Profit | 22 | 26 | 26 | 13 | 27 | 4 | 35 | 117 | 26 | 37 | 22 | 30 | 31 | |
| EPS in Rs | 13.36 | 15.64 | 16.00 | 8.01 | 16.18 | 2.54 | 21.12 | 70.95 | 15.90 | 22.28 | 13.38 | 18.08 | 18.48 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −1.33% · closed higher next day 0 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 28 Jul '26◦ |
| Earnings day | −1.33% |
| +1 day | −3.83% |
| +5 days | −6.26% |
| +15 days | −7.65% |
| +30 days | — |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Jun 202672.95%Promoter
Promoters72.95%
FIIs0.95%0.08
DIIs8.68%1.23
Public17.42%1.30
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,899.00 | 36.07 | 4,55,634 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,100.00 | 81.09 | 2,41,576 | 0.33% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,857.00 | 82.80 | 1,84,745 | 0.78% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| CIPLA | ₹1,385.00 | 31.26 | 1,11,888 | 0.94% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| ZYDUSLIFE | ₹1,120.00 | 22.95 | 1,11,720 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| LAURUSLABS | ₹1,840.00 | 90.93 | 99,417 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,110.00 | 16.20 | 96,483 | 0.85% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| RPGLIFE | ₹2,721.60 | 38.58 | 4,501 | 0.88% | 31 | +16.28% | 196 | +15.85% | 25.71% |
| Median: 158 Co. | ₹421.50 | 33.96 | 2,277 | 0.08% | 13 | +30.25% | 164 | +18.67% | 14.96% |
Filings
Annual reports15
Annual Report 2026bseAnnual Report 2025bseAnnual Report 2024bseAnnual Report 2023bseAnnual Report 2022bseAnnual Report 2021bseAnnual Report 2020bseAnnual Report 2019bseAnnual Report 2018bseAnnual Report 2017bseAnnual Report 2016bseAnnual Report 2015bseAnnual Report 2014bseAnnual Report 2013bseAnnual Report 2012bse
Concall transcripts49
PPTJun 2024PPTSep 2026PPTJul 2026TranscriptMay 2026PPTMay 2026RECMay 2026PPTApr 2026PPTJan 2026TranscriptOct 2025PPTOct 2025RECOct 2025PPTJul 2025PPTJun 2025TranscriptApr 2025PPTApr 2025RECApr 2025PPTNov 2024TranscriptSep 2024RECSep 2024PPTJul 2024TranscriptMay 2024PPTMay 2024PPTFeb 2024TranscriptOct 2023
Credit ratings6
Announcements5
Outcome Of Investors Meet 4 Sep - Company shared details of its September 3, 2026 analyst/institutional call on its website.Investors Meet 3 Sep - API business update investor call scheduled for September 3, 2026 at 4:00 PM IST.Announcement under Regulation 30 (LODR)-Press Release / Media Release 2 Sep - RPG Active Pharma acquires Raghava Life Sciences API business for up to ₹135 crore, adding 300 KL capacity.Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation 2 Sep - RPG Life Sciences will host an analyst/investor call on September 3, 2026 at 4:00 PM IST.Announcement under Regulation 30 (LODR)-Investor Presentation 2 Sep